Ed Gemo was Appointed as SVP/CIO at Turning Point Therapeutics

Date of management change: February 14, 2021 

What Happened?

San Diego, CA-based Turning Point Therapeutics Appointed Ed Gemo as SVP/CIO

 

About the Company

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

 

About the Person

Ed Gemo is SVP/CIO at Turning Point Therapeutics. Previously, Ed held various senior HR leadership roles in the industry.

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Lee Michelle, Raburn Mark, Gredinger Martin, Reed Megan, Philosophos Torger, Marcum Angela, Garciamendez Ezio, Hawley Kirsten, Christley Jon, Garza Denise, Lam Sharon

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.